
Opinion|Videos|September 13, 2024
Biosimilar Copay Programs
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses biosimilar copay programs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do copay programs impact the adoption of biosimilars for patients, and what role can the pharmacy staff play in educating patients about these programs?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Treatment of High-Risk Clear Cell RCC
4
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
5






























































































































